The DOI matches its Crossref record; 126 of the 126 references it cites were found in a registry or an index.
Comparative Tolerability of Newer Agents for Insomnia
Abstract
Newer treatment options for insomnia include the non-benzodiazepine hypnotics zolpidem, zolpidem-controlled release, zaleplon, zopiclone, eszopiclone and the melatonin receptor agonist, ramelteon. These compounds are generally well tolerated and present favourable safety profiles in comparison with the older benzodiazepines and barbiturates. Commonly cited impairments of memory formation and decrements in psychomotor performance are related to the mechanism of action of hypnotics, and are both dose- and time-dependent. These effects typically are minimal on the morning following night-time administration. The non-benzodiazepines are associated with some risk for dependence and abuse. However, concerns regarding such risks appear to be greater than warranted by empirical evidence. The appropriate therapeutic use of hypnotics is generally not associated with physiological responses that are commonly thought to lead to dependence, such as tolerance or discontinuation effects. Former substance abusers and psychiatric patients appear to be at greatest risk. The labelling of hypnotics was recently updated to incorporate warnings about very rare, but serious adverse events that have been identified in postmarketing surveillance. These events include anaphylaxis (severe allergic reaction); angio-oedema (severe facial swelling); and complex sleep-related behaviours, which may include sleep-driving, making phone calls and preparing and eating food. This article will review the adverse event profiles of these newer sedative hypnotics, their effects on memory and psychomotor performance, abuse liability concerns and the most recent information about the rare adverse effects that prompted the recent revision to the labelling of drugs in the hypnotic class.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In support of the latter hypothesis, ligands that do not bind to the α 5 subunit such as zolpidem have a reduced tendency to engender tolerance [158, 159]”
From Mechanisms Underlying Tolerance after Long-Term Benzodiazepine Use: A Future for Subtype-Selective Receptor Modulators? (2012) · cites this paper as [158]
In the citing paper
“suggesting that the prevalence of Z-drug misuse issues could have been underestimated compared with benzodiazepines (Zammit, 2009).”
From An Insight into Z-Drug Abuse and Dependence: An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions (2019) · cites this paper as Zammit, 2009
In the citing paper
“The present data may support previous hypotheses, for example, that there may be 2 subsets of individuals misusing Z-drugs; the first group may include patients with psychiatric comorbidities (Zammit, 2009; Lin et al., 2017), who were originally started with these molecules for insomnia but who developed tolerance and withdrawal phenomena, therefore requiring increasing dosages overtime (Griffiths”
From An Insight into Z-Drug Abuse and Dependence: An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions (2019) · cites this paper as Zammit, 2009
Citations
Cites
(1992) · Applied Ergonomics · doi:10.1016/0003-6870(92)90338-v · Cited by 7,112
Arky, R. A. (1994) · Cited by 2,632
Krystal, A. D., Walsh, J. K., Laska, E., Caron, J., Amato, D. A., Wessel, T. C., & Roth, T. (2003) · Sleep · doi:10.1093/sleep/26.7.793 · Cited by 630
An efficacy, safety, and dose–response study of Ramelteon in patients with chronic primary insomnia
ERMAN, M., SEIDEN, D., ZAMMIT, G., SAINATI, S., & ZHANG, J. (2006) · Sleep Medicine · doi:10.1016/j.sleep.2005.09.004 · Cited by 434
Self-citationHajak, G., Müller, W. E., Wittchen, H. U., Pittrow, D., & Kirch, W. (2003) · Addiction · doi:10.1046/j.1360-0443.2003.00491.x · Cited by 404
Holm, K. J., & Goa, K. L. (2000) · Drugs · doi:10.2165/00003495-200059040-00014 · Cited by 317
Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia
Zammit, G. K., McNabb, L. J., Caron, J., Amato, D. A., & Roth, T. (2004) · Current Medical Research and Opinion · doi:10.1185/174234304x15174 · Cited by 294
Self-citationClinical Pharmacokinetics and Pharmacodynamics of Zolpidem: Therapeutic Implications
Salvà, P., & Costa, J. (1995) · Clinical Pharmacokinetics · doi:10.2165/00003088-199529030-00002 · Cited by 273
Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia
Roth, T., Seiden, D., Sainati, S., Wang-Weigand, S., Zhang, J., & Zee, P. (2006) · Sleep Medicine · doi:10.1016/j.sleep.2006.01.003 · Cited by 265
Epidemiological Evidence for a Low Abuse Potential of Zolpidem
Soyka, M., Bottlender, R., & Möller, H.-J. (2000) · Pharmacopsychiatry · doi:10.1055/s-2000-11224 · Cited by 249
Research works printed but not linked: 31
- Scharf, 1994 May, J Clin Psychiatry, 55, 192
- Roger, 1993 Jan-Feb, Clin Ther, 15, 127
- Frattola, 1990, Drugs Exp Clin Res, 16, 371
- Scharf, 1991 Feb, J Clin Psychiatry, 52, 77
- Isawa, 2000 May, Nihon Shinkei Seishin Yakurigaku Zasshi, 20, 61
- Vermeeren, 2002 Mar 15, Sleep, 25, 224
- Griffiths, 2005, J Clin Psychiatry, 66, 31
- Gieschke, 1994 Nov, Methods Find Exp Clin Pharmacol, 16, 667
- Vermeeren, 1995, Acta Ther, 21, 47
- Uchiumi, 2000 Aug, Nihon Shinkei Seishin Yakurigaku Zasshi, 20, 123
- Tamminen, 1987, Sleep, 10, 63
- Ponciano, 1990 Apr, Int Clin Psychopharmacol, 5, 69
- Gary, 2004, Sleep, 27, A56
- Roth, 2005 Mar 1, Sleep, 28, 303
- Wang-Weigand, 2007, Sleep, 30, A244
- Hajak, 2007, Sleep, 30, A245
- Moldofsky, 1996 Mar, J Rheumatol, 23, 529
- Erman, 2007, Sleep, 30, A241
- Erman, 2007, Sleep, 30, A241
- Krystal, 2006, Sleep, 29, A249
- France, 2005, Sleep, 28, A45
- France, 2005, Sleep, 28, A45
- Nishida, 2005, Sleep, 28, A45
- Zammit, 2005, Sleep, 28, A228
- Karim, 2004, AAPS J, 6, R6196
- Tolbert, 2004, AAPS J, 6, R6195
- Karim, 2005, Sleep, 28, A45
- Maier, 2004, Sleep, 27, A56
- Karim, 2004, Sleep, 27, A53
- Karim, 2004, AAPS J, 6, R6197
- Najjar, 2007 Oct 15, J Clin Sleep Med, 3, 637, 10.5664/jcsm.26976 · DOI
Cited by
Cognitive Behavioral Therapy for Chronic Insomnia: A Systematic Review and Meta-analysis
Trauer, J. M., Qian, M. Y., Doyle, J. S., Rajaratnam, S. M. W., & Cunnington, D. (2015) · Annals of Internal Medicine · doi:10.7326/m14-2841 · Cited by 1,053
Morin, C. M., & Benca, R. (2012) · The Lancet · doi:10.1016/s0140-6736(11)60750-2 · Cited by 976
Melatonin and its analogs in insomnia and depression
Cardinali, D. P., Srinivasan, V., Brzezinski, A., & Brown, G. M. (2012) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2011.00962.x · Cited by 353
“In general, non-benzodiazepine sedative-hypnotics, although effective in reducing SOL, are only moderately effective in increasing sleep efficiency (SE) and TST [39].”
BackgroundGreenblatt, D. J., & Roth, T. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.667074 · Cited by 283
“Adverse reactions to zolpidem [65-69] generally are predictable consequences of its GABA-BZ agonist effects (Section 5).”
BackgroundSchifano, F., Chiappini, S., Corkery, J. M., & Guirguis, A. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz007 · Cited by 194
“, 2014), suggesting that the prevalence of Z-drug misuse issues could have been underestimated compared with benzodiazepines (Zammit, 2009).”
Influential
Metadata
- Authors
- Zammit, G.
- Affiliations
- Clinilabs (United States) (US)
- Corresponding author
- Zammit, Gary
- ORCID
- Zammit, Gary
- Venue
- Drug Safety
- Published
- 2009-09
- Volume
- 32
- Issue
- 9
- Pages
- 735-748
- ISSN
- 0114-5916 (ISSN-L)
- OpenAlex
- W2023944666
- Cited by
- 98
- References
- 126
- Citations by year
- 2026: 1 · 2025: 2 · 2023: 7 · 2022: 3 · 2021: 4 · 2020: 4 · 2019: 3 · 2018: 3 · 2017: 3 · 2016: 2 · 2015: 12 · 2014: 7 · 2013: 12 · 2012: 12
- FWCI
- 1.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drug Safety (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Keywords
- insomnia, non-benzodiazepine hypnotics, zolpidem, zaleplon, zopiclone, eszopiclone, ramelteon, melatonin receptor agonists, drug tolerability, adverse drug reactions, memory impairment, psychomotor performance, hypnotic dependence, abuse liability, drug labeling, anaphylaxis, angioedema, benzodiazepines, barbiturates
- MeSH terms
- Zolpidem, Clinical Trials as Topic, Drug Interactions, Humans, Hypnotics and Sedatives, Indenes, Sleep Initiation and Maintenance Disorders, Memory, Piperazines, Psychomotor Performance, Pyridines, Substance Withdrawal Syndrome, Randomized Controlled Trials as Topic, Substance-Related Disorders, Azabicyclo Compounds
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparative Tolerability of Newer Agents for Insomnia. https://app.cochat.ai/papers/10.2165/11312920-000000000-00000
- The paper
- Zammit, G. (2009). Comparative Tolerability of Newer Agents for Insomnia. Drug Safety. https://doi.org/10.2165/11312920-000000000-00000
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.